On April 1, 2021, Eloxx Pharmaceuticals, Inc., acquired Zikani Therapeutics, Inc., pursuant to that certain Agreement and Plan of Merger, dated April 1, 2021, by and among Eloxx, Delta Merger Sub Acquisition Corporation, a Delaware corporation and direct, wholly owned subsidiary of the Company (“Merger Sub”), and Zikani. Effective as of the effective time of the Merger on April 1, 2021, and pursuant to the Merger Agreement, (i) Sumit Aggarwal was appointed as the President and Chief Executive Officer of the Company, and in connection therewith, the Company and Mr. Aggarwal entered into an Employment Agreement effective as of April 1, 2021. On April 1, 2021, the Company and Dr. Gregory C. Williams entered into a Separation Agreement and General Release (the “Separation Agreement”) pursuant to which, among other things, the Company and Dr. Williams agreed that Dr. Williams would separate from service with the Company, resigning from his position as the Chief Executive Officer of the Company and all other offices of the Company, effective as of April 1, 2021. Mr. Aggarwal served as President and Chief Executive Officer of Zikani since 2019. Mr. Aggarwal joined Zikani in 2018 as Chief Financial Officer and Chief Business Officer. Prior to joining Zikani, from 2015 to 2018, Mr. Aggarwal served as acting President and Chief Financial Officer of Progenity, Inc.